C-J Advisory’s Amicus Therapeutics FOLD Stock Holding History

C-J Advisory’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-150	Closed	-$1K	–	82
2019 Q3	$1K	Hold	150	–	–	﹤0.01%	166
2019 Q2	$2K	Hold	150	–	–	﹤0.01%	167
2019 Q1	$2K	Hold	150	–	–	﹤0.01%	181
2018 Q4	$1K	Hold	150	–	–	﹤0.01%	155
2018 Q3	$2K	Hold	150	–	–	﹤0.01%	162
2018 Q2	$2K	Buy	+150	New	+$2.27K	﹤0.01%	163

Other funds holding FOLD

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

C-J Advisory's FOLD Position: Q4 2019 in Review

C-J Advisory sold out of Amicus Therapeutics (FOLD) in Q4 2019, closing a stake of 150 shares — an estimated $1K sold.

C-J Advisory first reported a position in FOLD in Q2 2018 and held it in 6 quarters. The position peaked at $2K in Q2 2019. 223 funds tracked by Wall St. Rank hold FOLD as of Q4 2019.

C-J Advisory reported no remaining Amicus Therapeutics position as of Q4 2019 after selling out during the quarter.
C-J Advisory sold 150 Amicus Therapeutics shares in Q4 2019, an estimated $1K.
C-J Advisory first reported a position in Amicus Therapeutics in Q2 2018 and held it in 6 quarters.
C-J Advisory's Amicus Therapeutics position peaked at $2K in Q2 2019.
223 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2019.

Based on C-J Advisory's 13F filing for Q4 2019, filed 10 Feb 2020.